91 related articles for article (PubMed ID: 17476038)
1. The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy.
Gurm HS; Rajagopal V; Bhatt DL; Ellis SG; Lincoff AM
J Invasive Cardiol; 2007 May; 19(5):225-8. PubMed ID: 17476038
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
Gurm HS; Rajagopal V; Fathi R; Vivekanathan D; Yadav JS; Bhatt DL; Ellis SG; Lincoff AM; Topol EJ
Am J Cardiol; 2005 Mar; 95(6):716-21. PubMed ID: 15757596
[TBL] [Abstract][Full Text] [Related]
3. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ;
Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bivalirudin and heparin in patients undergoing rotational atherectomy: a subanalysis of the randomised ROTAXUS trial.
Akin I; Khattab AA; Büttner HJ; Toelg R; Geist V; Neumann FJ; Richardt G; Abdel-Wahab M
EuroIntervention; 2014 Aug; 10(4):458-65. PubMed ID: 25138183
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
[TBL] [Abstract][Full Text] [Related]
9. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.
Shahzad A; Kemp I; Mars C; Wilson K; Roome C; Cooper R; Andron M; Appleby C; Fisher M; Khand A; Kunadian B; Mills JD; Morris JL; Morrison WL; Munir S; Palmer ND; Perry RA; Ramsdale DR; Velavan P; Stables RH;
Lancet; 2014 Nov; 384(9957):1849-1858. PubMed ID: 25002178
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
11. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM
J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449
[TBL] [Abstract][Full Text] [Related]
12. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
[TBL] [Abstract][Full Text] [Related]
14. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
[TBL] [Abstract][Full Text] [Related]
15. Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction.
Chu WW; Kuchulakanti PK; Wang B; Torguson R; Clavijo LC; Pichard AD; Suddath WO; Satler LF; Kent KM; Waksman R
Cardiovasc Revasc Med; 2006; 7(3):132-5. PubMed ID: 16945819
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.
Mishkel GJ; Moore AL; Markwell SJ; Ligon RW
J Invasive Cardiol; 2007 Feb; 19(2):63-8. PubMed ID: 17268039
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
Lee MS; Shlofmitz E; Nayeri A; Hollowed J; Kong J; Shlofmitz RA
J Invasive Cardiol; 2017 Nov; 29(11):397-400. PubMed ID: 29086730
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
Maroo A; Lincoff AM
Semin Thromb Hemost; 2004 Jun; 30(3):329-36. PubMed ID: 15282655
[TBL] [Abstract][Full Text] [Related]
19. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
